Vitrolife ABOSTO:VITR +0.11%79 ROA % is 3.61% as of Mar. 2026, which is 55% below its 10-year median of 8.03. GuruFocus rates OSTO:VITR with a GF Score™ of 79/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 80.51% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vitrolife AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr404 Mil.
Vitrolife AB's average Total Assets over the quarter that ended in Mar. 2026 was kr11,183 Mil. Therefore, Vitrolife AB's annualized ROA % for the quarter that ended in Mar. 2026 was 3.61%.
The historical rank and industry rank for Vitrolife AB's ROA % or its related term are showing as below:
OSTO:VITR'
s ROA % Range Over the Past 10 Years
Min: -35.09 Med: 8.03 Max: 19.96
Current: -34.46
During the past 13 years, Vitrolife AB's highest ROA % was 19.96%. The lowest was -35.09%. And the median was 8.03%.
OSTO:VITR's ROA % is ranked worse than 80.51% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.54
vs OSTO:VITR: -34.46
Vitrolife AB (OSTO:VITR) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Vitrolife AB ROA % Related Terms
Vitrolife AB ROA % Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vitrolife AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's ROA % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Vitrolife AB (OSTO:VITR) has a ROA % of 3.61% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vitrolife AB and its competitors. This is 55% below median its historical median of 8.03. According to the industry distribution chart, Vitrolife AB ranks #690 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 80.5%.
Is Vitrolife AB's ROA % too high?
Vitrolife AB's current ROA % of 3.61% is 55% below median its 10-year median of 8.03. The Medical Devices & Instruments industry median ROA % is 0.54. Vitrolife AB's value of 3.61% is 568.5% above this industry median. Based on the distribution chart, Vitrolife AB ranks #690 out of 857 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vitrolife AB has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #690 out of 857 companies for ROA %. This places Vitrolife AB in the lower half of its industry. The industry median ROA % is 0.54. Vitrolife AB's value of 3.61% is 568.5% above this benchmark. While the company's 10-year median is 8.03 vs. the industry median of 0.54, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.54, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current ROA % of 3.61% is 568.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current ROA % is 3.61%, which is 55% below median its own 10-year median of 8.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current ROA % is 3.61%, which is 55% below median its 10-year median of 8.03 and 568.5% above the Medical Devices & Instruments industry median of 0.54. Vitrolife AB's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current ROA % is 3.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
ROA %: 3.61% (55% below median its 10-year median of 8.03)
GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
Industry Position: 568.5% above the Medical Devices & Instruments median (#690 of 857)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
79GF Score
Get the complete analysis for OSTO:VITR
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
